Background macular Shape Background macular Shape Background macular Shape
Grants > Dark Matter: Developing a Nanoantioxidant-Based Therapeutic System for AMD Updated On: Jan. 21, 2025
Macular Degeneration Research Grant

Dark Matter: Developing a Nanoantioxidant-Based Therapeutic System for AMD

Innovative Approaches to Macular Degeneration Treatments
Yong-Su Kwon, PhD

Principal Investigator

Yongsu Kwon, PhD

University of North Carolina at Chapel Hill

Chapel Hill, NC, USA

About the Research Project

Program

Macular Degeneration Research

Award Type

Postdoctoral Fellowship

Award Amount

$200,000

Active Dates

July 01, 2022 - August 30, 2024

Grant ID

M2022001F

Goals

Our research aims to develop a novel effective antioxidant system to prevent and suppress age-related macular degeneration (AMD) pathological progression by ceria-coated melanin nanoparticles (CMNPs).

Summary

In Aim 1, we will focus on the antioxidative activity of ceria-coated melanin nanoparticles (CMNPs) in scavenging against multiple primary and secondary reactive oxide and nitrogen species (RONS), and demonstrate cytotoxicity and treatment efficacy using RONS-induced mouse primary retinal pigmented epithelial (mRPE) cells. In Aim 2, we will demonstrate that CMNPs ensure a long-term sustained release of antioxidants for neutralizing oxidative stress, and relieve pathological damages in an Nrf2-/- -CNV of new dry and a wet AMD-like mouse model through a single-dose intravitreal administration.

Unique and Innovative

This work provides a strategy of combining melanin nanoparticles with traditional cerium oxide nanoparticles (ceria) for the treatment of AMD. The designed ceria-coated melanin nanoparticles (CMNPs) provide a powerful treatment option for oxidative stress-induced pathogenesis such as AMD by taking advantage of inherent antioxidant ability of melanin and ceria to create a unique synergistic approach. Our strategy will ensure the autoregenerative properties and more efficacious antioxidant activities of CMNPs for sustained therapy as robust reactive oxide and nitrogen species scavengers.

Foreseeable Benefits

This novel strategy is designed to overcome both forms of wet and dry AMD. Our findings will add a new, potentially powerful treatment option for patients with AMD, and be used in treatments for several other diseases, such as neurodegenerative disorders and diabetic retinopathy, which have oxidative stress in common and are challenged by current standard approaches. The designed ceria-coated melanin nanoparticles (CMNPs) could function as an alternative to natural melanin in RPE cells, providing insight into future directions as a novel approach to overcome dysfunction of melanin.